🔗 Share this article

A shadow economy for unlicensed slimming drugs is propelled by social media fitness personalities and sellers on communication apps, based on new investigations.

Experimental Drug Acquiring Traction Online

Retatrutide, which remains in clinical trials, is being advertised by online personalities for its alleged fat-burning properties. Followers are encouraged to contact these accounts privately for supplier links, while also obtaining promotional offers.

Thriving Commerce on Messaging Platforms

Additionally, a flourishing trade exists on messaging services, where groups with thousands of participants share comparison photos, administration instructions and claims of next-day UK delivery. Sellers market the drug there before redirecting customers to other platforms for transactions.

Understanding Retatrutide

This medication is an investigational injection developed by American pharmaceutical company Eli Lilly. The treatment affects three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials indicate it could assist patients lose up to 25% of their body weight. Referred to as the “triple G”, the drug is being hailed digitally as the successor to Ozempic.

Healthcare Experts Express Concerns

However, physicians and pharmacists have warned that the sale of what is still an unlicensed drug in the UK is a cause for concern and could lead to users administering substances of uncertain source.

Several professionals stated the demand for retatrutide could be connected to the increasing cost of approved slimming treatments such as Mounjaro.

Legal Status and Enforcement

Selling retatrutide on social media or messaging apps is illegal in the United Kingdom, as it is an unapproved medication that must not be promoted or distributed for human use under the British medical regulations.

Some influencers attempt to circumvent the regulations by referring to the drug as a “research chemical” or citing it as “not for human consumption”. The substance is not a controlled drug, but advertising and supply can still breach pharmaceutical, marketing, and customer laws, potentially leading to fines, legal action or imprisonment.

Service Response and Material Elimination

Based on the social media company, the platform has removed problematic content and banned associated hashtags and query recommendations. The organization stated it was committed to keeping the platform safe and investing in strengthening enforcement strategies.

Digital Trading Activities

Investigations also discovered groups with up to nine thousand members selling retatrutide using Telegram's integrated discovery tool, which operates like a online catalog. Typing “retatrutide” immediately brings up channels with thousands of members, filled with photos of slimming results, positive reviews and detailed instructions for mixing or administering at residence.

Within moments of joining one group, a seller posted WhatsApp details, where most purchases occur. The vendor provided an guidebook and promised shipping within two days. When questioned whether the substance was genuine, one seller said: “You can’t be sure.” Another provided a photo of a supposed testing documentation. None asked about weight, health issues or previous experience.

Product Information and Costs

Within these groups, posts display dark colored packages with postal service labels, claiming to include fresh supplies. One communication stated: “It took eight of us to load them this morning.”

Customers can select between powder vials, prepared at residence with sterile water, or pre-filled injectors typically priced at 160 pounds for 20mg. When asked how much time a pen should be used, sellers give contradictory responses ranging from a few weeks to “depends on your body”.

Platform Oversight and Safety Actions

A spokesperson for the messaging service said it regularly monitored harmful material on its platform including content that promoted the “misuse of controlled medications”. The organization noted that it eliminated “millions of pieces of harmful content each day”.

Healthcare Expert Cautions

“People are administering substances they cannot confirm. Even if the research behind this drug is valid, these digital products may not contain what they advertise,” stated a pharmacy expert, the head of pharmacy at Chemist4U.

Dr Crystal Wyllie of Asda Online Doctor linked the surge in demand to current price rises for authorized weight-loss drugs such as Mounjaro. “With prices increasing, patients are turning to social media. But fake treatments are extremely risky. You cannot know what’s inside or whether the conditions they were produced in was clean,” she explained.

Her staff has previously encountered patients harmed by self-injection from unverified sources. “We recognize the frustration, but buying from Telegram or WhatsApp is gambling with your health,” stated the doctor. “These substances could be contaminated or incorrectly dosed.”

Manufacturer Position

A representative from the pharmaceutical company stated the substance was in phase 3 research studies and had not been reviewed or authorized by any government authority globally. “Therefore at this point no one can market [it] for personal consumption,” they explained, noting that any product “falsely representing itself as a company experimental product not yet authorized … may expose patients to possibly significant health risks”.